Type 2 diabetes: The one major change you can make to help reverse the condition

TYPE 2 diabetes is regarded as a lifelong condition, but with certain lifestyle changes, the condition can be controlled. But is it possible to put the condition into remission? New evidence has suggested this may be possible.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news

Related Links:

In a society where physical activity is limited and food supply is abundant, metabolic diseases are becoming a serious epidemic. Metabolic syndrome (MetS) represents a cluster of metabolically related symptoms such as obesity, hypertension, dyslipidemia, and carbohydrate intolerance, and significantly increases type 2 diabetes mellitus risk. Insulin resistance and hyperinsulinemia are consistent characteristics of MetS, but which of these features is the initiating insult is still widely debated. Regardless, both of these conditions trigger adverse responses from the pancreatic β cell, which is responsible for produci...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
This study aimed to explore the association between thyroid dysfunction and OSA in the adults with prediabetes or diabetes mellitus type 2, who have very high prevalence of OSA.MethodsOSA was assessed using an in-home monitoring device, WatchPAT200. OSA severity was measured using apnea-hypopnea index (AHI), oxygen desaturation index (ODI), minimum oxygen saturation (minO2), and time spent under oxygen saturation
Source: Sleep and Breathing - Category: Respiratory Medicine Source Type: research
AbstractBackgroundThyroid dysfunction (TD) occurs in 13.4% of diabetic patients, which has prompted recommendations for annual thyroid screening in patients with diabetes. However, recommendations for annual screening should be based on disease incidence rather than prevalence.MethodsIn 1997 –1998, seven hundred and thirty patients (618 type 2 diabetes, 55% male; 112 type 1 diabetes, 47% male) were sequentially screened for TD. The 639 patients with normal thyroid function were followed from 1999 to 2006, with annual thyroid function tests.ResultsA total of 21/112 (19%) with type 1 diabetes (T1DM) and 70/618 (11%) wi...
Source: Irish Journal of Medical Science - Category: General Medicine Source Type: research
PMID: 31426060 [PubMed - in process]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
PMID: 31426059 [PubMed - in process]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
PMID: 31426058 [PubMed - in process]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
Many studies have demonstrated that an alteration in hemorheological properties, such as red blood cell (RBC) deformability, is closely correlated with diabetic microcirculatory diseases. However, most of these studies have been limited to animal studies or used a small number of clinical samples, due to a lack of effective point-of-care (POC) devices to measure such properties within clinical environments. Owing to recent developments in microfluidic technology, several hemorheological POC devices have been designed that allow for the possibility of conducting extensive clinical studies using hemorheological measurements....
Source: Frontiers in Physiology - Category: Physiology Source Type: research
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Source: Endocrine - Category: Endocrinology Source Type: research
Many patients with type 2 diabetes are overtreated, leading to more than 9000 preventable hospital visits over 2 years, a modeling study found.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Condition:   Type 2 Diabetes With Renal Manifestations Interventions:   Drug: Semaglutide, 1.34 mg/mL;   Other: Placebo, 1,34 mg/mL;   Drug: Empagliflozin 25 MG Sponsors:   Steno Diabetes Center Copenhagen;   Novo Nordisk A/S Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diabetes | Diabetes Type 2 | Endocrinology | Health